International Journal of Molecular Sciences · 2024 · 11 citations · 35 references
MedicineCell BiologyOncologyBreast OncologyCell DifferentiationMolecular OncologyCancer ProgressionCancer Stem Cell BiologyCancer Stem Cell HeterogeneityCancer Stem Cell MaintenanceCancer Stem CellsStem Cell DifferentiationCancer Stem Cell MarkersCancer Stem Cell Phenotypic HeterogeneityCancer Stem Cell TraitsCd133 ExpressionCd44 ExpressionPrimary Tumor CharacterizationStem Cell Marker ExpressionStemness Heterogeneity
Most studies on CTCs have focused on isolating cells that express EpCAM. In this study, we emphasize the presence of EpCAM-negative and EpCAMlow CTCs, in addition to EpCAMhigh CTCs, in early BC. We evaluated stem cell markers (CD44/CD24 and CD133) and EMT markers (N-cadherin) in each subpopulation. Our findings indicate that all stemness variants were present in both EpCAMhigh and EpCAM-negative CTCs, whereas only one variant of stemness (nonCD44+CD24−/CD133+) was observed among EpCAMlow CTCs. Nearly all EpCAMhigh CTCs were represented by CD133+ stem cells. Notably, the hybrid EMT phenotype was more prevalent among EpCAM-negative CTCs. scRNA-seq of isolated CTCs and primary tumor partially confirmed this pattern. Therefore, further investigation is imperative to elucidate the prognostic significance of EpCAM-negative and EpCAMlow CTCs.
35
Steven J. Cohen, Cornelis J.A. Punt, Nicholas Iannotti et al. · Journal of Clinical Oncology · 2008 · 1.8K citations · Full text